RxDoctor Payments Data

Jose Ramos, MD

Cardiovascular Disease · San Juan, PRNPI 1841210077

Payments from drug & device makers

$3,698in general payments, 2019–2025

Across 111 payments — averaging $33.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • E.r. Squibb & Sons, L.L.C.$526
  • Boehringer Ingelheim$454
  • Johnson & Johnson$404
  • AstraZeneca$250
  • Novo Nordisk$242
  • plus $758 from 8 others

What the payments were for

  • Food & beverage$3,698100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,698 in reported general payments places this provider in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

See all cardiovascular disease providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$28,654
Medicare patients
109
Services billed
518

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban309$196,905
JardianceEmpagliflozin144$103,851
FarxigaDapagliflozin Propanediol131$87,069
XareltoRivaroxaban120$83,339
TradjentaLinagliptin141$82,273
JanuviaSitagliptin Phosphate120$80,762
Janumet XrSitagliptin Phos/Metformin Hcl61$48,951
JanumetSitagliptin Phos/Metformin Hcl61$46,687
SynthroidLevothyroxine Sodium652$46,096
GlyxambiEmpagliflozin/Linagliptin62$40,972
Trijardy XrEmpaglifloz/Linaglip/Metformin52$37,634
BrilintaTicagrelor30$20,474
Metoprolol Succinate1,352$19,707
Synjardy XrEmpagliflozin/Metformin Hcl21$15,827
Candesartan-HydrochlorothiazidCandesartan/Hydrochlorothiazid147$15,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Glyxambi, Trijardy Xr, Synjardy Xr$454$280,557420 claims
MerckJanuvia, Janumet Xr, Janumet$22$176,400242 claims
AstraZenecaFarxiga, Brilinta, Symbicort$250$111,300177 claims
Johnson & JohnsonXarelto$404$83,339120 claims
Sanofi-aventis U.S. LLCLantus$12$8,22460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 267 cardiovascular disease providers in Puerto Rico.

Other cardiovascular disease in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →